Transparent Weighting of Heterogeneous Evidence for Auditable Candidate Prioritization
- 1VNU University of Science
Abstract
Motivation: Differential-expression and network-based prioritization capture complementary molecular evidence. However, integrating these criteria poses a trade-off between score integration and methodological transparency. Existing approaches derive weights through optimization against predictive or benchmark metrics, or use manual or equal-weight settings without explicitly encoding the rationale for relative criterion importance. Results: We introduce AHP-CDS, an auditable candidate-ranking method that makes criterion importance explicit through weights derived from the Analytic Hierarchy Process from explicit pairwise judgments, which allows the resulting rankings to be evaluated through consistency, sensitivity and contribution analyses. The resulting pairwise judgments achieved acceptable consistency (Consistency Ratio = 0.050). The leave-one-criterion-out analysis showed that ranking sensitivity followed the assigned weight ordering: the removal of Fold-change producing most of the disruption (Spearman compare to full method ρ = 0.796), whereas removing betweeness causes the least (ρ = 0.992). Score decomposition further made individual rank changes traceable to their evidence dimension. Contact: [email protected] or [email protected] Availability: all code is uploaded on \url{https://github.com/NguyenMauTue/PRIDE-breast-cancer-exosome-biomarker-discovery} Supplementary: Is all posted online
Related
- Hyperbolic heterogeneous graph learning for adverse drug reaction prediction, candidate prioritization, and pathway-based interpretation in pharmacovigilance
- Deploying YOLO for whole-slide mitosis detection: A transparent, auditable, and reproducible pipeline for pathology AI-assisted diagnosis and decision-support tool
- Structure-based computational prioritization of Emodin-8-glucoside as a candidate ligand for the VEGFR1 kinase domain in the context of placenta previa
- Multi-Omics Prioritization and Clinical Evaluation of CYP4V2 as a Candidate Biomarker in Venous Thromboembolism.
- Per- and polyfluoroalkyl substances and kidney disease: Genetic associations and computational prioritization of candidate toxicogenomic pathways
BibTeX
@misc{nguyen2026transparent,
title = {{Transparent Weighting of Heterogeneous Evidence for Auditable Candidate Prioritization}},
author = {T. M. Nguyen},
howpublished = {bioRxiv},
year = {2026},
month = may,
doi = {10.64898/2026.05.14.725271},
url = {https://www.biorxiv.org/content/10.64898/2026.05.14.725271v6},
note = {CC BY},
}
RIS
TY - UNPB
TI - Transparent Weighting of Heterogeneous Evidence for Auditable Candidate Prioritization
AU - T. M. Nguyen
PY - 2026
DA - 2026/05/14
PB - bioRxiv
DO - 10.64898/2026.05.14.725271
UR - https://www.biorxiv.org/content/10.64898/2026.05.14.725271v6
AB - Motivation: Differential-expression and network-based prioritization capture complementary molecular evidence. However, integrating these criteria poses a trade-off between score integration and methodological transparency. Existing approaches derive weights through optimization against predictive or benchmark metrics, or use manual or equal-weight settings without explicitly encoding the rationale for relative criterion importance. Results: We introduce AHP-CDS, an auditable candidate-ranking method that makes criterion importance explicit through weights derived from the Analytic Hierarchy Process from explicit pairwise judgments, which allows the resulting rankings to be evaluated through consistency, sensitivity and contribution analyses. The resulting pairwise judgments achieved acceptable consistency (Consistency Ratio = 0.050). The leave-one-criterion-out analysis showed that ranking sensitivity followed the assigned weight ordering: the removal of Fold-change producing most of the disruption (Spearman compare to full method ρ = 0.796), whereas removing betweeness causes the least (ρ = 0.992). Score decomposition further made individual rank changes traceable to their evidence dimension. Contact: [email protected] or [email protected] Availability: all code is uploaded on \url{https://github.com/NguyenMauTue/PRIDE-breast-cancer-exosome-biomarker-discovery} Supplementary: Is all posted online
ER -